Sequoia Financial Advisors LLC Has $1.70 Million Stake in Edwards Lifesciences Corporation (NYSE:EW)

Sequoia Financial Advisors LLC boosted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 190.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 23,495 shares of the medical research company's stock after acquiring an additional 15,417 shares during the period. Sequoia Financial Advisors LLC's holdings in Edwards Lifesciences were worth $1,703,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Crowley Wealth Management Inc. bought a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $26,000. Vega Investment Solutions acquired a new stake in Edwards Lifesciences in the 4th quarter valued at approximately $27,000. Millstone Evans Group LLC bought a new stake in Edwards Lifesciences in the 4th quarter valued at approximately $29,000. Global X Japan Co. Ltd. boosted its position in Edwards Lifesciences by 116.1% during the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after acquiring an additional 216 shares during the last quarter. Finally, ORG Wealth Partners LLC bought a new position in shares of Edwards Lifesciences during the 1st quarter worth approximately $38,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

Shares of EW stock traded down $1.00 during midday trading on Tuesday, hitting $77.21. 3,124,860 shares of the company were exchanged, compared to its average volume of 5,233,531. Edwards Lifesciences Corporation has a 52 week low of $58.93 and a 52 week high of $95.25. The firm has a market capitalization of $45.29 billion, a P/E ratio of 11.03, a PEG ratio of 3.94 and a beta of 1.11. The firm's 50 day moving average price is $75.80 and its two-hundred day moving average price is $73.18. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 4.45.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The firm had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. During the same period last year, the business posted $0.66 earnings per share. The business's revenue for the quarter was up 6.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on EW. Dbs Bank raised shares of Edwards Lifesciences to a "hold" rating in a research report on Monday, June 2nd. Truist Financial cut their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Robert W. Baird increased their price objective on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research note on Thursday, April 24th. Wall Street Zen downgraded Edwards Lifesciences from a "buy" rating to a "hold" rating in a research report on Friday, May 16th. Finally, Piper Sandler increased their price target on Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a research report on Tuesday, May 13th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $80.20.

Insider Transactions at Edwards Lifesciences

In other news, VP Daveen Chopra sold 1,500 shares of Edwards Lifesciences stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $75.08, for a total transaction of $112,620.00. Following the completion of the sale, the vice president owned 33,496 shares of the company's stock, valued at approximately $2,514,879.68. This trade represents a 4.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Bernard J. Zovighian sold 5,980 shares of the firm's stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $74.91, for a total transaction of $447,961.80. Following the transaction, the chief executive officer directly owned 58,284 shares in the company, valued at approximately $4,366,054.44. This represents a 9.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 40,648 shares of company stock worth $2,998,866. 0.34% of the stock is currently owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.